Citadel Advisors
CERE

Citadel Advisors’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Citadel Advisors’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-955,818
Closed -$39.1M – 15635
2024
Q2 		$39.1M Buy
955,818
+871,933
+1,039% +$36.3M 0.01% 1348
2024
Q1 		$3.55M Sell
83,885
-169,747
-67% -$7.13M ﹤0.01% 4520
2023
Q4 		$10.8M Buy
253,632
+102,704
+68% +$2.95M ﹤0.01% 2743
2023
Q3 		$3.29M Buy
150,928
+65,049
+76% +$1.63M ﹤0.01% 4319
2023
Q2 		$2.73M Buy
85,879
+51,446
+149% +$1.58M ﹤0.01% 4627
2023
Q1 		$840K Buy
34,433
+30,233
+720% +$887K ﹤0.01% 7175
2022
Q4 		$132K Sell
4,200
-61,221
-94% -$1.73M ﹤0.01% 10801
2022
Q3 		$1.85M Sell
65,421
-400,613
-86% -$11.9M ﹤0.01% 5739
2022
Q2 		$12.3M Buy
466,034
+448,943
+2,627% +$12.7M ﹤0.01% 2413
2022
Q1 		$598K Sell
17,091
-326,353
-95% -$9.53M ﹤0.01% 8968
2021
Q4 		$11.1M Sell
343,444
-238,871
-41% -$8.43M ﹤0.01% 2897
2021
Q3 		$17.2M Sell
582,315
-169,850
-23% -$4.77M ﹤0.01% 2226
2021
Q2 		$19.3M Sell
752,165
-474,564
-39% -$6.79M ﹤0.01% 2132
2021
Q1 		$16.8M Sell
1,226,729
-154,827
-11% -$2.27M ﹤0.01% 2185
2020
Q4 		$22.9M Buy
+1,381,556
New +$17.9M 0.01% 1659

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Citadel Advisors's CERE Position: Q3 2024 in Review

Citadel Advisors sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 955,818 shares — an estimated $39.1M sold.

Citadel Advisors first reported a position in CERE in Q4 2020 and held it in 15 quarters. The position peaked at $39.1M in Q2 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Citadel Advisors reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Citadel Advisors sold 955,818 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $39.1M.
  • Citadel Advisors first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2020 and held it in 15 quarters.
  • Citadel Advisors's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $39.1M in Q2 2024.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Citadel Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.